drugset
drugset / Trial / NCT01579084

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

NCT01579084 ↗

Phase 1 Completed 64 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and tolerability of AGN-199201 for the treatment of erythema associated with rosacea.

Timeline

Start
2012-04
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxymetazoline Other / unclassified — Topical

Indications

rosacea